难以治疗的类风湿性关节炎:我们学到了什么,还有什么需要学习?
Zonne L M Hofman1, Nadia M T Roodenrijs1, Elena Nikiphorou2,3
1Department of Rheumatology and Clinical Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Rheumatology (Oxford, England)
|October 9, 2024
概括
难以治疗的类风湿性关节炎 (D2T RA) 影响5.5-27.5%的患者. 了解多因素驱动因素,包括并发症和社会经济因素,对于优化D2T RA管理至关重要.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 临床医学 临床医学
背景情况:
- 难以治疗的类风湿性关节炎 (D2T RA) 是一个重要的未满足的医疗需求.
- 根据初始队列研究,D2T RA的患病率估计在5.5%至27.5%之间.
- D2T RA的特点是,尽管至少有两种生物或有针对性的合成DMARDs失败,但疾病管理存在问题.
研究的目的:
- 审查有助于D2T RA的生物和非生物因素.
- 确定优化D2T RA患者治疗策略的关键驱动因素.
- 为了利用新出现的D2T RA队列数据的见解.
主要方法:
- 现有文献和来自D2T RA队列研究的患者数据的综述.
- 对影响RA治疗结果的生物和非生物因素的分析.
- 在D2T RA子组内识别共同和独特的特征.
主要成果:
- D2T RA是多因素的,在一些子组中观察到高患病率和较低的社会经济地位.
- 在D2T RA中,即使没有可识别的并发症或社会经济因素,也可能出现持久症状.
- 患者数据突显了D2T RA的异质性和需要个性化评估.
结论:
- 一个整体的方法是必要的,以确定个别的D2T RA患者的潜在问题.
- 优化生物和非生物驱动因素对于有效的D2T RA管理是必要的.
- 对D2T RA驱动器的进一步研究将为改进的治疗策略提供信息.
相关概念视频
01:21Rheumatic Heart Disease III: Medical Management
3
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
3
01:20Rheumatic Heart Disease IV: Nursing Management
5
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
5
01:20The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
8
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
8
01:29Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143